Roche
Pharmaceuticals, diagnostics and digital health software for healthcare.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- F. Hoffmann-La Roche Ltd
- Entity type
- COMPANY
- Founded
- 1896
- Headquarters
- Grenzacherstrasse 124, 4058 Basel
- Company size
- >5,000
- Market role
- Other / Non-Digital Advertising Relevant
- Official website
- roche.com
What Roche does
Roche runs a diversified healthcare model combining biopharma R&D, diagnostics manufacturing and enterprise healthcare software. It creates value by discovering and commercialising medicines, selling diagnostic platforms and consumables into clinical settings, and embedding software such as navify into laboratory and care workflows to improve operational performance and strengthen customer retention across the diagnostics ecosystem.
Category differentiation
Roche is a global healthcare manufacturer and diagnostics company, not an adtech, martech or media platform. Its navify products are clinical and laboratory software tools, not advertising analytics products.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Roche is a Swiss multinational healthcare company that develops, manufactures and sells pharmaceuticals, diagnostics and related digital health solutions. Its core business is organised around Pharmaceuticals and Diagnostics, with the navify portfolio extending the Diagnostics division into enterprise software for hospitals, laboratories and healthcare systems. The company operates globally and reports group-level results at scale. Roche generates revenue primarily from prescription medicines, diagnostic instruments, tests, reagents and associated healthcare software. Its software products are sold to enterprise healthcare customers through subscriptions, licences, bundled solutions and service agreements, while patient-facing digital properties support clinical trial awareness and engagement rather than serving as the primary revenue engine.
Company news briefing
Briefing updated:
Building on its post-pandemic recovery, Roche reports 7% base business growth led by its Vabysmo and Ocrevus franchises. The group is accelerating its entry into the obesity and metabolic disease markets whilst prioritising AI-driven diagnostics to drive operating profit. Alongside its previously reported deployment of 90,000 generative AI seats, Roche has formalised these strategic pillars in a recent investor presentation and scheduled a Pharma Day for September 2026 to further detail its clinical pipeline and digitisation efforts.
Business model & monetisation
Roche monetises through a mix of pharmaceutical product sales, diagnostic instrument placements, recurring consumables and enterprise software revenue. Digital products such as navify are commercialised as SaaS platforms, software licences, bundled workflow solutions and long-term service agreements tied to diagnostics infrastructure. This creates recurring revenue through reagent pull-through, maintenance, software subscriptions and enterprise account expansion.
- Pharmaceutical product sales
- One-time Sale
- Diagnostic instruments, tests and reagents
- One-time Sale
- Enterprise healthcare software subscriptions
- Software Subscription
- Service, support and workflow agreements
- Service Fee
Products & capabilities
No products with linked sources are available in this view.
Products & market categories
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Roche Pharma Day 2026 announced
Recorded impact score: 1/5
Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.
Roche and Ypsomed Stay Top in Swiss Reputation Ranking
Public Relations · Recorded impact score: 2/5
Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.
- Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
- The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
Investor Presentation Released: Roche
financials · Recorded impact score: 4/5
AI parsed presentation narrative: Roche is successfully transitioning to a post-pandemic growth phase, with base business growth of 7% and core operating profit expanding faster than sales. The strategy focuses on maximizing high-growth franchises like Vabysmo and Ocrevus while aggressively expanding into the obesity market and AI-driven diagnostics. Strategic pillars: Maximizing value of existing growth drivers, Leading in Obesity and Metabolic disease.
Explore company relationships
Questions about Roche
What is Roche?
Roche is a Swiss healthcare company that develops pharmaceuticals, diagnostics and enterprise digital health software for clinical and laboratory settings.
Who uses Roche?
Roche is used by hospitals, clinical laboratories, health systems, pathologists, healthcare professionals and procurement teams; patients mainly use its clinical trial information platform.
How does Roche make money?
Roche makes money from selling medicines, diagnostic instruments, tests, reagents and enterprise software subscriptions, licences and service agreements.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
17 publicly documented primary sources and citations linked across the market graph.
Continue your research on Roche
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.